November 08, 2022
Three weeks after Teva Pharmaceuticals opened a patent infringement suit by accusing Eli Lilly and Co. of free riding on intellectual property undergirding its migraine drug, Lilly told the jury Tuesday its rival is the real culprit after it "hopped into a de-risked market."
October 19, 2022
Teva Pharmaceuticals kicked off its migraine drug patent infringement trial against Eli Lilly and Co. on Wednesday, telling a Boston federal jury that the rival shouldn't be allowed to "free ride" on its hard-won research to rake in sales for a similar treatment.
April 01, 2020
The Patent Trial and Appeal Board upheld all claims in three Teva Pharmaceutical patents covering its migraine biologic Ajovy that were challenged by Eli Lilly, giving a boost to Teva's underlying infringement suit against its rival over a competing drug.